Skip to Main Content

Paper Details

Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data.
Prostate Cancer and Prostatic Diseases
3
2021
Docetaxel, TRDD, bilirubin, chronic kidney disease, diabetes, docetaxel, mCRPC, metastatic castration-resistant prostate cancer, patient, patients
Author NameAffiliation
Matthew D GalskyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
William K OhTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  • 1 - 2

Datasets

Release 1.2